Cambridge Healthtech Institute’s 16th Annual
Clinical Biomarkers and Companion Diagnostics
Collaborating to Drive Precision Medicine Forward
August 19-20, 2025
As medicine becomes increasingly personalized, clinical biomarkers and companion diagnostics are valuable tools for advancing precision therapeutics. Navigating challenges in regulatory approval and patient access remains a top priority in strategic biotherapeutic development. Join Cambridge Healthtech Institute’s 16th Annual conference on Clinical Biomarkers and Companion Diagnostics, where speakers and attendees will confer on the latest regulatory updates, drug-diagnostic co-development strategies, avenues for commercial success, and reducing barriers to patient access. This conference is an opportunity to connect with industry leaders, regulators, clinicians, diagnostic manufacturers, and policymakers who are working on the next generation of tools for precision medicine.
Coverage will include, but is not limited to:
- Enhancing partnerships and drug-diagnostic co-development
- Multi-stakeholder perspectives on diagnostic development
- Exploring avenues for commercialization
- Global and local regulatory frameworks and pathways
- Biomarker-driven therapeutic development
- Biomarkers and diagnostics in oncology and non-oncology indications, including CNS and rare diseases
- Addressing clinical practice gaps in patient access to biomarker testing
- Impact of policy changes on personalized medicine
The deadline for priority consideration is January 27, 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: